{"entity":{"id":"nct06157892","kind":"trial","name":"A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors","aka":[],"tldr":"A phase 2 trial of Disitamab vedotin and Tucatinib in gastric & gastro-oesophageal junction cancer, HER2-positive breast cancer and triple-negative breast cancer, run by Seagen, a wholly owned subsidiary of Pfizer, active and no longer recruiting.","summary":"A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors is a phase 2 interventional study registered as NCT06157892 by Seagen, a wholly owned subsidiary of Pfizer, with 54 participants enrolled, started 2024-05-20 and due to reach its primary completion in 2029-07-28. Interventions recorded: disitamab vedotin and tucatinib.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06157892","url":"https://clinicaltrials.gov/study/NCT06157892"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gastric","breast-her2-positive","tnbc"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["disitamab-vedotin","tucatinib"],"companies":["remegen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06157892","phase":"2","setting":"A Phase 1b/2 Open-Label Study of Disitamab Vedotin in Combination With Other Anticancer Therapies in Solid Tumors","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","participation":[{"nct":"NCT06157892","source":"https://clinicaltrials.gov/study/NCT06157892","fetchedAt":"2026-10-07T16:54:16.815Z","studySha256":"9e35a745450062194335f672a2e680290ca627cb148b88dd873f01f23b6e3395","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-07-22","leadSponsor":"Seagen, a wholly owned subsidiary of Pfizer","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":54,"enrolmentType":"ACTUAL","siteCount":135,"recruitingSiteCount":0,"countries":["Australia","Canada","Germany","Italy","Japan","South Korea","Spain","Taiwan","United Kingdom","United States"]}],"started":"2024-05-20","startedType":"actual","enrolled":54,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06157892/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"disitamab-vedotin","kind":"drug","name":"Disitamab vedotin","route":"/drugs/disitamab-vedotin/"},{"id":"tucatinib","kind":"drug","name":"Tucatinib","route":"/drugs/tucatinib/"}],"company":[{"id":"remegen","kind":"company","name":"RemeGen","route":"/companies/remegen/"}],"institution":[{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/"}]}}